Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Mar-2017
No. of pages: 250
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Summary

The Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies

Global Orphan Diseases Partnering 2010 to 2017 provides the full collection of Orphan Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Orphan Diseases partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Orphan Diseases partnering agreement structure

Orphan Diseases partnering contract documents

Top Orphan Diseases deals by value

Most active Orphan Diseases dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.

The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Orphan Diseases dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Orphan Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Orphan Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Orphan Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Orphan Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Orphan Diseases partnering deals by specific Orphan Diseases target announced since 2010. The chapter is organized by specific Orphan Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Orphan Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Orphan Diseases partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Orphan Diseases technologies and products.

Report scope

Global Orphan Diseases Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Orphan Diseases trends and structure of deals entered into by leading companies worldwide.

Global Orphan Diseases Partnering 2010 to 2017 includes:

Trends in Orphan Diseases dealmaking in the biopharma industry since 2010

Analysis of Orphan Diseases deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Orphan Diseases deal contract documents

Comprehensive access to over 3500 Orphan Diseases deal records

The leading Orphan Diseases deals by value since 2010

Most active Orphan Diseases dealmakers since 2010

In Global Orphan Diseases Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Orphan Diseases Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 100 orphan diseases deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Orphan Diseases Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Orphan Diseases deal trends since 2010

Access Orphan Diseases deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Orphan Diseases partner companies

Comprehensive access to over 750 links to actual Orphan Diseases deals entered into by the world's biopharma companies

Indepth review of Orphan Diseases deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Orphan Diseases opportunities

Uncover companies actively partnering Orphan Diseases opportunities

Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Orphan Diseases dealmaking

2.1. Introduction
2.2. Orphan Diseases partnering over the years
2.3. Orphan Diseases partnering by deal type
2.4. Orphan Diseases partnering by industry sector
2.5. Orphan Diseases partnering by stage of development
2.6. Orphan Diseases partnering by technology type
2.7. Orphan Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Orphan Diseases partnering

3.1. Introduction
3.2. Disclosed financials terms for Orphan Diseases partnering
3.3. Orphan Diseases partnering headline values
3.4. Orphan Diseases deal upfront payments
3.5. Orphan Diseases deal milestone payments
3.6. Orphan Diseases royalty rates

Chapter 4 - Leading Orphan Diseases deals and dealmakers

4.1. Introduction
4.2. Most active in Orphan Diseases partnering
4.3. List of most active dealmakers in Orphan Diseases
4.4. Top Orphan Diseases deals by value

Chapter 5 - Orphan Diseases contract document directory

5.1. Introduction
5.2. Orphan Diseases partnering deals where contract document available

Chapter 6 - Orphan Diseases dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Orphan Diseases therapeutic target

Appendices

Appendix 1 - Directory of Orphan Diseases deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Orphan Diseases deals by deal type 2010 to 2017
Appendix 3 - Directory of Orphan Diseases deals by stage of development 2010 to 2017
Appendix 4 - Directory of Orphan Diseases deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Orphan Diseases partnering since 2010
Figure 2: Orphan Diseases partnering by deal type since 2010
Figure 3: Orphan Diseases partnering by industry sector since 2010
Figure 4: Orphan Diseases partnering by stage of development since 2010
Figure 5: Orphan Diseases partnering by technology type since 2010
Figure 6: Orphan Diseases partnering by indication since 2010
Figure 7: Orphan Diseases deals with a headline value
Figure 8: Orphan Diseases deals with upfront payment values
Figure 9: Orphan Diseases deals with milestone payment
Figure 10: Orphan Diseases deals with royalty rates
Figure 11: Active Orphan Diseases dealmaking activity- 2010 to 2017
Figure 12: Top Orphan Diseases deals by value since 2010
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia-Pacific Minocycline Hydrochloride Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 27-Apr-2017        Price: US 4480 Onwards        Pages: 123
    Minocycline Hydrochloride, also called minocycline HCL, is a broad-spectrum tetracycline antibiotic, and has a broader spectrum than the other members of the group. It is a bacteriostatic antibiotic, classified as a long-acting type. As a result of its long half-life it generally has serum levels 2-4 times that of the simple water-soluble tetracyclines. The CAS?Number?is 13614-98-7. Scope of the Report: This report focuses on the Minocycline Hydrochloride in Asia-Pa......
  • Global Dyslipidemia Drugs Market Professional Survey Report 2017
    Published: 26-Apr-2017        Price: US 3500 Onwards        Pages: 113
    This report studies Dyslipidemia Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - AstraZeneca - Merck - Pfizer - Bayer - Abbott Laboratories......
  • Global Measles Vaccine Market Research Report 2017
    Published: 26-Apr-2017        Price: US 2900 Onwards        Pages: 116
    In this report, the global Measles Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Measles Vaccine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Jap......
  • Global Oral Rotavirus Vaccine Market Research Report 2017
    Published: 26-Apr-2017        Price: US 2900 Onwards        Pages: 102
    In this report, the global Oral Rotavirus Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Oral Rotavirus Vaccine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Chin......
  • EMEA (Europe, Middle East and Africa) Anti-Infective Drugs Market Report 2017
    Published: 26-Apr-2017        Price: US 4000 Onwards        Pages: 110
    In this report, the EMEA Anti-Infective Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Anti-Infective Drugs for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux;......
  • Global Poliomyelitis Vaccine Market Research Report 2017
    Published: 26-Apr-2017        Price: US 2900 Onwards        Pages: 101
    In this report, the global Poliomyelitis Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Poliomyelitis Vaccine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • Global Meningitis Vaccine Market Research Report 2017
    Published: 26-Apr-2017        Price: US 2900 Onwards        Pages: 101
    In this report, the global Meningitis Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Meningitis Vaccine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China ......
  • 2017-2022 China Travelers Vaccines Market Report (Status and Outlook)
    Published: 25-Apr-2017        Price: US 3360 Onwards        Pages: 119
    The Travelers Vaccines market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - GlaxoSmithKline/Novartis - Sanofi Pasteur - Pfizer - Merck - Sanofi Pasteur MSD - CNBG - Biokangtai ......
  • 2017-2022 Germany Travelers Vaccines Market Report (Status and Outlook)
    Published: 25-Apr-2017        Price: US 3360 Onwards        Pages: 119
    The Travelers Vaccines market size will be XX million (USD) in 2022 in Germany, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Germany market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - GlaxoSmithKline/Novartis - Sanofi Pasteur - Pfizer - Merck - Sanofi Pasteur MSD - CNBG - Biokangtai ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs